Advertisement
Advertisement

TheBodyPRO.com covers IAS 2013

Monthly or Quarterly Injectable HIV Antiretrovirals Are Safe and Effective in Early Study

August 5, 2013

GSK744, an investigational integrase inhibitor, and TMC278 LA (a long-acting, injectable form of the NNRTI rilpivirine [Edurant]) both showed safety and efficacy when administered in once-monthly or once-quarterly doses, according to a study presented at IAS 2013. There were no drug-related serious adverse events and all adverse events were either mild or moderate.

The phase 1 study, conducted by GlaxoSmithKline and Janssen, assessed the safety, tolerability, and pharmacokinetics of GSK744 (when given intramuscularly or subcutaneously) in conjunction with TMC278 LA (injected intramuscularly). The researchers enrolled 47 HIV-uninfected individuals (17 female and 30 male) with a median age of 39.5. Thirty-five were white, 10 black, and two of another race.

All patients were given an oral lead-in of GSK744 (also known as S/GSK1265744) at 30 mg/day for 14 days, followed by a week-long break, to assess safety and tolerability. Seven of the 47 patients discontinued the oral GSK744 because of non-drug-related adverse events or dizziness. The remaining 40 were given an 800-mg "loading dose" of GSK744 through intramuscular injection, and then randomized into four cohorts.

Advertisement
  • Cohort 1 received three monthly doses of GSK744 at 200 mg via subcutaneous injection (at weeks 4, 8 and 12), without TMC278 LA.
  • Cohort 2 received three monthly doses of GSK744 at 200 mg via intramuscular injection (at weeks 4, 8 and 12), with TMC278 LA via intramuscular injection (1,200 mg at week 8 and 900 mg at week 12).
  • Cohort 3 received three monthly doses of GSK744 at 400 mg via intramuscular injection (at weeks 4, 8 and 12), with TMC278 LA via intramuscular injection (1,200 mg at week 8 and 600 mg at week 12).
  • Cohort 4 received a second dose of GSK744 at 800 mg (at week 12), without TMC278 LA.

All four cohorts showed relevant plasma concentrations of the drugs within three days, meaning concentration levels were high enough to be considered effective. Between doses, concentration levels remained well above 90% inhibitory concentration (IC90) for both GSK744 and TMC278. The plasma concentration levels of TMC278 LA were comparable to taking oral rilpivirine at 25 mg/day.

Three people withdrew during the injection phase, two for non-drug-related adverse events and one for self-limited rash. The most common event not related to injection site reaction (ISR) was headache, but there were no serious adverse events (grade 4 or higher). Local ISRs were common, but generally well tolerated and self-limited.

The researchers concluded that injections of GSK744 with TMC278 LA were safe and generally well tolerated in healthy adults, with monthly or quarterly doses showing long-lasting and effective levels of plasma concentrations. Further study and clinical evaluation will be needed.

While these drugs are still in early stages of study, the hope is that they can act as long-lasting PrEP (pre-exposure prophylaxis) or effective treatment for HIV-infected patients that could replace daily pills.

View the study abstract and presentation slides.

Warren Tong is the research editor for TheBody.com and TheBodyPRO.com.

Follow Warren on Twitter: @WarrenAtTheBody.


Copyright © 2013 Remedy Health Media, LLC. All rights reserved.



This article was provided by TheBodyPRO.com. It is a part of the publication The 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.
 


 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement